WeetmanAP. 2000. Graves' disease. N Engl J Med, 343:1236–1248.
2.
AniszewskiJP, ValyaseviRW, BahnRS. 2000. Relationship between disease duration and predominant orbital T cell subset in Graves' disease. J Clin Endocrinol Metab, 85:776–780.
3.
WakelkampIM, BakkerO, BaldeschiL, WiersingaWM, PrummelMF. 2003. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf), 58:280–287.
BonecchiR, BianchiG, BordignonPP, D'AmbrosioD, LangR, BorsattiA, SozzaniS, AllavenaP, GrayPA, MantovaniA, SinigagliaF. 1998. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med, 187:129–134.
6.
SallustoF, LenigD, MackayCR, LanzavecchiaA. 1998. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med, 187:875–883.
7.
FranciottaD, MartinoG, ZardiniE, FurlanR, BergamaschiR, AndreoniL, CosiV. 2001. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol, 115:192–198.
8.
NicolettiF, CongetI, Di MauroM, Di MarcoR, MazzarinoMC, BendtzenK, MessinaA, GomisR. 2002. Serum concentrations of the interferon-gamma-inducible chemokin IP-10/CXCL10 are augmented in both newly diagnosed type 1 diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia, 45:1107–1110.
9.
AntonelliA, RotondiM, FallahiP, RomagnaniP, FerrariSM, BuonamanoA, FerranniniE, SerioM. 2004. High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab, 89:5496–5499.
10.
García-LópezMA, SanchoD, Sánchez-MadridF, MarazuelaM. 2001. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab, 86:5008–5016.
11.
KempEH, MetcalfeRA, SmithKA, WoodroofeMN, WatsonPF, WeetmanAP. 2003. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf), 59:207–213.
12.
RomagnaniP, RotondiM, LazzeriE, LasagniL, FrancalanciM, BuonamanoA, MilaniS, VittiP, ChiovatoL, TonaccheraM, BellastellaA, SerioM. 2002. Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves' disease. Am J Pathol, 161:195–206.
13.
RotondiM, LazzeriE, RomagnaniP, SerioM. 2003. Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest, 26:177–180.
14.
AntonelliA, FallahiP, RotondiM, FerrariSM, RomagnaniP, GrossoM, FerranniniE, SerioM. 2006. Increased serum CXCL10 in Graves' disease or autoimmune thyreoditis is associated with hyper- or hypothyreoidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol, 154:651–658.
15.
GalimbertiD, ScalabriniD, FenoglioC, ComiC, De RizM, VenturelliE, LovatiC, MarianiC, MonacoF, BresolinN, ScarpiniE. 2007. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. Eur J Neurol, 14:162–167.
16.
VenturelliE, GalimbertiD, FenoglioC, LovatiC, FinazziD, GuidiI, CorràB, ScalabriniD, ClericiF, MarianiC, ForloniG, BresolinN, ScarpiniE. 2006. Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. Neurosci Lett, 404:217–221.
17.
ZhangJ, NoguchiE, MigitaO, YokouchiY, NakayamaJ, ShibasakiM, ArinamiT. 2005. Association of a haplotype block spanning SDAD1 gene and CXC chemokine genes with allergic rhinitis. J Allergy Clin Immunol, 115:548–554.
FujiiH, ShimadaY, HasegawaM, TakeharaK, SatoS. 2004. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci, 35:43–51.
20.
BugejaMJ, BoothDR, BennettsBH, HeardRNS, StewartGJ. 2006. An investigation of polymorphisms in the 4q13.3-21.1 CXC chemokin gene cluster for association with multiple sclerosis in Australians. Mult Scler, 12:710–722
21.
BartalenaL, PincheraA, MarcocciC. 2000. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev, 21:168–199.
22.
BednarczukT, GopinathB, PloskiR, WallJR. 2007. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack?Clin Endocrinol (Oxf), 67:3–19.
